Insulin-Like Growth Factor Binding Protein 2

01/01/2019 - "Clinical studies demonstrate that circulating IGFBP-2 levels associated inversely with body mass index (BMI) and insulin resistance. "
01/01/2012 - "The aim of this study was to evaluate insulin resistance and IGFBP-2 levels in SGA children, and to identify the effect of catch-up growth on IGFBP-2 concentration. "
10/01/2010 - "Circulating IGFBP-2 was positively associated with insulin sensitivity, in agreement with previous studies. "
12/01/2019 - "These results show that PPAR-γ2, C/EBP-α, FOXO1 and IGFBP-2 have a close relationship with insulin resistance in VAT of morbidly obese individuals."
02/01/2019 - "After adjustment for insulin sensitivity, high IGFBP-2 levels are predictive of increased mortality."

01/01/2001 - "In a follow-up study, plasma IGFBP-2 concentration remained stable in patients with complete remission or stabilized disease and was a late marker of tumor progression in patients with progressive metastatic disease. "
01/01/2001 - "There was no significant difference in plasma IGFBP-2 concentration between healthy controls and patients with complete remission or localized tumors. "
05/29/2008 - "Furthermore, significantly greater levels of IGFBP-2 antibody immunity were found in cancer patients compared to normal controls (p = 0.008). "
09/01/2012 - "Our results first demonstrate IGFBP-2 Abs for early cancer detection and in combination of serum IGFBP-2 for improved cancer diagnosis."
01/01/2022 - "The prognostic significance of insulin-like growth factor binding protein 2 (IGFBP2) expression has been explored in plenty of studies in human cancers. "

12/01/2019 - "Additionally, HSP60 and IGFBP-2 levels also strongly correlated with extension of liver metastases and exhibited a prognostic value that contrasted that of CEA."
03/06/2010 - "In particular, increased levels of IGFBP-2 expression are associated with advanced PCa, bone metastasis, and the development of castrate resistant PCa. "
11/01/2000 - "We tested the potential tumour marker characteristics of IGFBP-2 SDS against three endpoints: metastasis alone; local pelvic recurrence alone; and metastasis and recurrence combined. "
06/01/2015 - "Finally, preclinical studies have demonstrated that IGFBP-2 administration can be beneficial in improving metabolic responses (inhibition of adipogenesis and enhanced insulin sensitivity), while blockade of IGFBP-2 appears to be an effective approach to inhibiting tumour growth and metastasis. "
01/01/2021 - "Our results also revealed that uPA is a downstream target of IGFBP-2 to intermediate oral cancer metastasis. "

01/01/2019 - "Recent studies suggest that insulin-like growth factor binding protein 2 (IGFBP-2) may protect against type 2 diabetes, but population-based human studies are scarce. "
01/01/2019 - "We aimed to investigate the prospective association of circulating IGFBP-2 concentrations and of differential methylation in the IGFBP-2 gene with type 2 diabetes risk."
01/01/2019 - "Insulin-Like Growth Factor Binding Protein 2 (IGFBP-2) and the Risk of Developing Type 2 Diabetes."
06/01/2014 - "Overexpression of IGFBP-2 protects against obesity and type 2 diabetes. "
06/01/2011 - "IGFBP-2 concentrations are reduced in obesity, and further reductions are seen in those with Type 2 diabetes. "

06/01/2018 - "These findings suggest that reduced levels of IGFBP-2 may play an important role in the pathogenesis of obesity complications in early life."
05/01/2015 - "Overexpression of IGFBP-2 in transgenic mice prevents obesity, but depot-specific effects of IGFBP-2 on adipo/lipogenesis are unknown. "
07/06/2012 - "Although IGFBP-2 derives mostly from the liver, recent evidence in mice and humans indicate that aging and obesity are associated with altered IGFBP-2 levels in white adipocytes. "
06/01/2011 - "IGFBP-2 may be integrally involved in the molecular processes that govern the development of obesity and subsequent weight-related disease. "
02/01/2007 - "These findings suggest an important, novel role for IGFBP-2 in obesity prevention."